AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$LIVN

LivaNova PLC Q3 2026 Earnings Call Summary

LivaNova PLC raised its full-year 2026 revenue guidance to 9-10% growth and adjusted EPS to $4.40-$4.50. Growth was driven by record Essence heart-lung machine placements, epilepsy volume growth, and reduced discounting. The company plans to enter the obstructive sleep apnea (OSA) market in 2027 and expects double-digit capacity expansion in 2027 due to new manufacturing lines. Management highlighted strong demand for oxygenators and strategic initiatives to support future growth.

Original reporting
finance.yahoo.com
Published Nov 4, 2026, 11:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 11:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
LivaNova PLC Q3 2026 Earnings Call Summary — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$LIVNBullishMed
01

Why it matters

The guidance raise reflects higher demand and operational efficiencies, likely prompting a price rally.

02

Market read

Guidance upgrade is a material new development for a mid‑cap medical‑device stock, offering a clear trading catalyst.

03

What to watch

Potential regulatory delays for OSA PMA submission and tariff exposure could affect margins.

Relevance 7/10Novelty 8/10Timing: after-hours

Background

LivaNova's Q3 2026 earnings call highlighted operational expansions, new product lines, and a shift in SNIA payment timing.

Company-level read

Ticker impact

$LIVNBullishHigh confidence
Context

LivaNova raised its full-year 2026 revenue guidance by 9-10% and EPS to $4.40-$4.50 during its Q3 earnings call.

Expected impact

likely upward pressure as investors price in higher revenue and earnings expectations

Evidence & confidence

Guidance upgrades are a direct catalyst that typically moves the share price in the direction of the news.

Market effects

Sector

Improved outlook for the cardiopulmonary and neuromodulation sectors may lift peers.

Regional

U.S. healthcare investors may see a modest rally.

Global

Limited to medical device market; no broad macro effect.

Counterpoint

What could challenge this read

If the guidance assumes optimistic demand for OSA products, execution risk could temper upside.

Key entities

  • Company
    LivaNova PLC

    Medical device maker focusing on cardiopulmonary and neuromodulation products.

Read at source← All news

StoryLivaNova posts Q3 2026 earnings beat and lifts full‑year revenue and EPS guidance

Also covered by

6 outlets

Related articles

$LIVNMed

LivaNova PLC (LIVN) (Q3 2026) Earnings Call Highlights: Double-Digit Growth Fuels

LivaNova PLC (LIVN) reported Q3 2026 earnings with adjusted free cash flow declining to $56M from $62M YoY. SG&A expenses rose to $136M from $123M, and a $400M payment shifted to Q4, creating cash flow uncertainty. The company expects 1% FX tailwind but $5M tariff headwinds. Cardiopulmonary growth remains strong, with double-digit increases, and the next-gen oxygenator launch is on track for 2028.

finance.yahoo.com
$LIVNMed

Mizuho raises Livanova stock price target on Essenz placements

Mizuho raised its price target for Livanova (LIVN) to $115 from $95, citing strong U.S. Cardiopulmonary segment growth and Essenz placements. The stock has risen 48% in the past year, trading at $96.59. Livanova reported Q3 2026 earnings of $1.23 per share, beating estimates, and raised its full-year outlook. Jefferies also increased its price target to $120.

investing.com
$LIVNHighAI 8/10

Jefferies raises Livanova stock price target to $120 on guidance

Jefferies increased its price target for LivaNova (NASDAQ:LIVN) to $120 from $100, maintaining a Buy rating. The company reported Q3 sales of $393M, up 10%, and EPS of $1.23, up 20%, both beating estimates. LivaNova raised its full-year sales growth guidance to 9-10% and EPS guidance to $4.40-$4.50. The stock has a market cap of $5.33B and a PEG ratio of 0.12, according to InvestingPro.

investing.com